Black Diamond Therapeutics (BDTX) vs Coherus Oncology (CHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Black Diamond Therapeutics (BDTX) has outperformed Coherus Oncology (CHRS) over the past year, losing 65.5% versus a loss of 68.1%. Over five years, BDTX leads with a -79.3% price change compared with -98.0% for CHRS. Black Diamond Therapeutics is the larger company by market cap ($75.3 million vs $57.1 million), about 1.3 times the size.
Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus 32.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | CHRS |
|---|---|---|
| Share price | $1.31 | $0.3698 |
| Market cap | $75.28M | $57.15M |
| 1-day change | -5.76% | -4.47% |
| YTD return | -46.09% | -73.96% |
| 1-year return | -65.53% | -68.12% |
| 5-year return | -79.30% | -97.99% |
| EPS (TTM) | $-0.77 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $70.00M | $42.17M |
| Revenue growth (YoY) | — | +59.81% |
| Net income (latest FY) | $22.37M | $168.02M |
| Gross margin | — | 67.24% |
| Operating margin | 17.89% | -429.51% |
| Net margin | 31.95% | 398.43% |
| 52-week high | $3.97 | $2.62 |
| 52-week low | $1.31 | $0.3628 |
| Distance from 52-week high | -67.00% | -85.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +663.36% | +1995.73% |
| Average volume | 697.70K | 1.80M |
| Shares outstanding | 57.47M | 154.54M |
| Employees | 21 | 144 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus 32.0 cents for Black Diamond Therapeutics.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
BDTX vs CHRS FAQ
Which is bigger, Black Diamond Therapeutics or Coherus Oncology?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $75.28M compared with $57.15M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, BDTX or CHRS?
BDTX returned -65.53% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Coherus Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.